礼来超越联合健康，成为全球最大的医疗保健公司_老虎社区_美港股上老虎

礼来超越联合健康，成为全球最大的医疗保健公司

环球市场播报2023-07-06

礼来成为全球市值最大的医疗保健公司，领先于健康保险巨头联合健康。该制药商周三上涨0.9%，在连续四个月上涨后扩大涨幅，今年其市值增加超过940亿美元。礼来6月份收盘价创下历史新高。礼来公司的崛起得益于其以Mounjaro为首的治疗肥胖症的药物系列，该药物已被批准用于治疗糖尿病，以及阿尔茨海默病的实验性治疗药物。此次上涨使礼来公司成为今年迄今为止标普500制药指数中表现最好的股票。联合健康收盘...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2349846690?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/902c608377ddcfec4660e51d435b9bdc","is_english":false,"pubTime":"2023-07-06 05:31","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2349846690","market":"us","top_or_hot":-1,"title":"礼来超越联合健康，成为全球最大的医疗保健公司","media":"环球市场播报","content":"<div>\n<p>礼来成为全球市值最大的医疗保健公司，领先于健康保险巨头联合健康。该制药商周三上涨0.9%，在连续四个月上涨后扩大涨幅，今年其市值增加超过940亿美元。 礼来6月份收盘价创下历史新高。礼来公司的崛起得益于其以Mounjaro为首的治疗肥胖症的药物系列，该药物已被批准用于治疗糖尿病，以及阿尔茨海默病的实验性治疗药物。 此次上涨使礼来公司成为今年迄今为止标普500制药指数中表现最好的股票。联合健康收盘...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/usstock/c/2023-07-06/doc-imyzswtw9182520.shtml\">网页链接</a>\n\n</div>\n","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>礼来超越联合健康，成为全球最大的医疗保健公司</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n礼来超越联合健康，成为全球最大的医疗保健公司\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-07-06 05:31 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/stock/usstock/c/2023-07-06/doc-imyzswtw9182520.shtml><strong>环球市场播报</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>礼来成为全球市值最大的医疗保健公司，领先于健康保险巨头联合健康。该制药商周三上涨0.9%，在连续四个月上涨后扩大涨幅，今年其市值增加超过940亿美元。 礼来6月份收盘价创下历史新高。礼来公司的崛起得益于其以Mounjaro为首的治疗肥胖症的药物系列，该药物已被批准用于治疗糖尿病，以及阿尔茨海默病的实验性治疗药物。 此次上涨使礼来公司成为今年迄今为止标普500制药指数中表现最好的股票。联合健康收盘...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/usstock/c/2023-07-06/doc-imyzswtw9182520.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4154","symbol_name":"管理型保健护理","start_time":0,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2023-07-06/doc-imyzswtw9182520.shtml","article_id":"2349846690","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/902c608377ddcfec4660e51d435b9bdc"],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/usstock/c/2023-07-06/doc-imyzswtw9182520.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2349846690","pubTimestamp":1688592660,"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"　　礼来成为全球市值最大的医疗保健公司，领先于健康保险巨头联合健康。礼来6月份收盘价创下历史新高。　　礼来公司的崛起得益于其以Mounjaro为首的治疗肥胖症的药物系列，该药物已被批准用于治疗糖尿病，以及阿尔茨海默病的实验性治疗药物。此次上涨使礼来公司成为今年迄今为止标普500制药指数中表现最好的股票。　　联合健康收盘下跌1.4%，今年迄今已下跌11%。","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4154":"管理型保健护理","SG9999018857.SGD":"United Global Quality Growth Fd Cl Acc SGD-H","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","LU0211326755.USD":"TEMPLETON GLOBAL INCOME \"A\" (USD) ACC","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","IE00BFSS8Q28.SGD":"Janus Henderson Balanced A Inc SGD-H","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LLY":"礼来","LU0211326839.USD":"TEMPLETON GLOBAL INCOME \"A\" (USD) INC","BK4581":"高盛持仓","SG9999014880.SGD":"大华全球优质成长基金Acc SGD","SG9999017495.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"B\" (SGD) ACC","IE00B7KXQ091.USD":"Janus Henderson Balanced A Inc USD","IE00BFSS7M15.SGD":"Janus Henderson Balanced A Acc SGD-H","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","SG9999014914.USD":"UNITED GLOBAL QUALITY GROWTH (USDHDG) INC","SG9999018865.SGD":"United Global Quality Growth Fd Cl Dist SGD-H","LU0238689110.USD":"贝莱德环球动力股票基金","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","IE00B19Z9505.USD":"美盛-美国大盘成长股A Acc","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","LU0079474960.USD":"联博美国增长基金A","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","UNH":"联合健康","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","IE00B1XK9C88.USD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A\" (USD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","BK4585":"ETF&股票定投概念","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00BJJMRY28.SGD":"Janus Henderson Balanced A Inc SGD","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","BK4007":"制药","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4566":"资本集团","LU0058720904.USD":"联博国际健康护理基金A","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)"},"translate_title":"Eli Lilly surpassed United Health to become the largest health care company in the world","themeId":"","isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/c01d2d1615a99862ab3fb5e46eb19fea","symbols_score_info":{"UNH":1,"LLY":1},"content_text":"礼来成为全球市值最大的医疗保健公司，领先于健康保险巨头联合健康。该制药商周三上涨0.9%，在连续四个月上涨后扩大涨幅，今年其市值增加超过940亿美元。 礼来6月份收盘价创下历史新高。礼来公司的崛起得益于其以Mounjaro为首的治疗肥胖症的药物系列，该药物已被批准用于治疗糖尿病，以及阿尔茨海默病的实验性治疗药物。 此次上涨使礼来公司成为今年迄今为止标普500制药指数中表现最好的股票。联合健康收盘下跌1.4%，今年迄今已下跌11%。BMO资本市场分析师埃文·塞格曼在接受采访时表示，礼来公司“在治疗肥胖方面的成功以及在较小程度上的阿尔茨海默氏症是推动这一趋势的原因”“他们不仅拥有药物，而且有能力成功地将其商业化并上市。”","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}